Vectus Biosystems Limited
Vectus Biosystems Limited is a drug discovery and development company based in North Ryde, Sydney. Using its platform technology, Vectus has constructed a library of more than 200 small molecules with varying degrees of anti-hypertensive and/or anti-fibrotic properties.
Fibrosis, the formation of excess fibrous connective tissue in an organ, plays a role in more than 40% of deaths worldwide. This figure includes different diseases affecting the heart, lungs, kidneys, and liver, among others. While current treatments only slow the progression of fibrosis, Vectus has demonstrated in animal models that its compounds can reverse the process, leading to the restoration of normal tissue architecture.
To-date, Vectus has identified drug targets with specific activity in the heart, kidneys, lungs, and liver.
The Company’s lead compound, VB0004, has potent anti-hypertensive properties, as well as anti-fibrotic activity in the heart and kidneys. Vectus also aims to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases.
Vectus Biosystems Limited holds patents around the Vasoactive Intestinal Peptide (VIP) and its fragments as a therapeutic candidate to treat cardiovascular fibrosis and systolic blood pressure.